Bensler LLC grew its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 9.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,476 shares of the company’s stock after purchasing an additional 1,344 shares during the period. Eli Lilly and Company comprises about 1.4% of Bensler LLC’s investment portfolio, making the stock its 22nd biggest holding. Bensler LLC’s holdings in Eli Lilly and Company were worth $11,948,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of the business. Algert Global LLC boosted its holdings in Eli Lilly and Company by 27.9% in the second quarter. Algert Global LLC now owns 504 shares of the company’s stock worth $456,000 after purchasing an additional 110 shares during the last quarter. RiverFront Investment Group LLC bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $256,000. Anchor Investment Management LLC boosted its stake in shares of Eli Lilly and Company by 0.9% in the 2nd quarter. Anchor Investment Management LLC now owns 13,966 shares of the company’s stock worth $12,645,000 after buying an additional 131 shares during the last quarter. Centaurus Financial Inc. grew its holdings in shares of Eli Lilly and Company by 102.4% in the second quarter. Centaurus Financial Inc. now owns 6,099 shares of the company’s stock worth $5,522,000 after acquiring an additional 3,085 shares during the period. Finally, Greater Midwest Financial Group LLC increased its position in Eli Lilly and Company by 230.2% during the second quarter. Greater Midwest Financial Group LLC now owns 4,018 shares of the company’s stock valued at $3,744,000 after acquiring an additional 2,801 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Insider Buying and Selling at Eli Lilly and Company
In other news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on LLY
Eli Lilly and Company Price Performance
LLY stock opened at $823.59 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The company’s fifty day moving average price is $780.80 and its 200-day moving average price is $845.98. Eli Lilly and Company has a one year low of $637.00 and a one year high of $972.53. The company has a market capitalization of $781.85 billion, a PE ratio of 89.04, a price-to-earnings-growth ratio of 1.59 and a beta of 0.41.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 12.98 EPS for the current fiscal year.
Eli Lilly and Company declared that its board has approved a stock buyback plan on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its shares are undervalued.
Eli Lilly and Company Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a yield of 0.73%. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Investing in Travel Stocks Benefits
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- What Are Dividend Achievers? An Introduction
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.